S100A4 expression is a prognostic indicator in small intestine adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Roh, Jin | - |
dc.contributor.author | Knight, Spencer | - |
dc.contributor.author | Chung, Joon-Yong | - |
dc.contributor.author | Eo, Soo-Heang | - |
dc.contributor.author | Goggins, Michael | - |
dc.contributor.author | Kim, Jihoon | - |
dc.contributor.author | Cho, HyungJun | - |
dc.contributor.author | Yu, Eunsil | - |
dc.contributor.author | Hong, Seung-Mo | - |
dc.date.accessioned | 2021-09-05T10:48:32Z | - |
dc.date.available | 2021-09-05T10:48:32Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-03 | - |
dc.identifier.issn | 0021-9746 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99085 | - |
dc.description.abstract | Aims Due to the rarity of small intestine adenocarcinoma (SIAC), estimating the prognosis for patients with surgically resected SIAC is difficult. Overexpression of S100A4 has been linked to worse patient survival in several malignant neoplasms, but its significance in SIAC has not been determined. Methods S100A4 protein expression was assessed in 197 surgically resected SIAC cases and compared with clinicopathological factors, including patient survival. Results A progressive increase in S100A4 labelling was observed in normal intestinal epithelium, adenoma and adenocarcinoma (p<0.001), and 50 SIAC cases (26.2%) showed strong S100A4 expression. Patients with SIAC with strong S100A4 expression had a higher pT classification (p=0.05), as well as increased lymph node metastasis (p=0.009) and perineural invasion (p=0.002). Patients with SIAC with strong S100A4 expression had significantly worse survival (median survival, 21 months) than those with weak/ no S100A4 expression (42.5 months) by univariable (p=0.04) and multivariable (p=0.01) analyses. Conclusions S100A4 overexpression is observed in a subset of SIACs, is associated with advanced disease and can be used as a prognostic indicator of poor prognosis in patients with SIAC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.subject | MTS1 GENE OVEREXPRESSION | - |
dc.subject | SMALL-BOWEL CANCER | - |
dc.subject | PROTEIN S100A4 | - |
dc.subject | E-CADHERIN | - |
dc.subject | UNITED-STATES | - |
dc.subject | METASTASIS | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | SURVIVAL | - |
dc.subject | P9KA | - |
dc.title | S100A4 expression is a prognostic indicator in small intestine adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cho, HyungJun | - |
dc.identifier.doi | 10.1136/jclinpath-2013-201883 | - |
dc.identifier.scopusid | 2-s2.0-84894253123 | - |
dc.identifier.wosid | 000331338300005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PATHOLOGY, v.67, no.3 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PATHOLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL PATHOLOGY | - |
dc.citation.volume | 67 | - |
dc.citation.number | 3 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | MTS1 GENE OVEREXPRESSION | - |
dc.subject.keywordPlus | SMALL-BOWEL CANCER | - |
dc.subject.keywordPlus | PROTEIN S100A4 | - |
dc.subject.keywordPlus | E-CADHERIN | - |
dc.subject.keywordPlus | UNITED-STATES | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | P9KA | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.